US 6,306,604 B1Granted

EPO primary response gene, EPRG3Spt

AssigneeSmithKline Beecham Corporation

InventorsSusan B Dillon, Kenneth A Lord

Life of this patent

Estimating the term…

Abstract

EPRG3Spt polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing EPRG3Spt polypeptides and polynucleotides in therapy, and diagnostic assays for such.

Claims5

Dependent claims

An isolated polypeptide comprising the amino acid sequence set forth in SEQ ID NO:

Dependencies are inferred from the claim text.

Facts

Application: 09/495,082Filed 31 Jan 2000 · division
Priority: 1 Aug 1997
Granted: 23 Oct 2001
Term ends: Not estimatedThe source records don’t support an estimate.

Classification7 codes

C07K 14/47
From vertebrates: from mammals
A61P 7/06
Drugs for disorders of the blood or the extracellular fluid: antianaemics
A61K 38/00
Medicinal preparations containing peptides
A61K 48/00
Medicinal preparations containing genetic material which is inserted into cells of the

Family

Application60/054,464Us provisional application · filed 1 Aug 1997
Application09/127,424Parent of this division · filed 31 Jul 1998
US 6,306,604 B1This patent

From the US filing history. Foreign family members aren’t listed.

Timeline

Citations

Open elsewhere

patentgrep

Loading patent…

patentgrepSearch patents

Back to results